A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

No abstract is available for this paper.

• Publication year

  2010

• Venue

  American journal of hematology/oncology

• Publication date

  2010-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ajh.21664PMID 20229590PMCID PMC4420736
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long‐term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia

  2014cited by this paper
• Cancer Statistics, 2009

  2010cited by this paper
• The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation

  2010cited by this paper
• A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.

  2009cited by this paper
• RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia

  2009cited by this paper
• Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

  2009cited by this paper
• Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.

  2009cited by this paper
• A complex interplay between Akt, TSC2 and the two mTOR complexes.

  2009cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

  2009cited by this paper
• Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.

  2008cited by this paper
• Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

  2008cited by this paper
• Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

  2008cited by this paper
• Beneficial Effect of Omega-3 Fatty Acids on Sirolimus- or Everolimus-Induced Hypertriglyceridemia in Heart Transplant Recipients

  2008cited by this paper
• Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.

  2008cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

  2008cited by this paper
• Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma

  2008cited by this paper
• Multiple Complete Responses in a Phase 1 Dose-Escalation Study of the Antibody-Drug Conjugate SGN-35 in Patients with Relapsed or Refractory CD30-Positive Lymphomas.

  2008cited by this paper
• Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502

  2008cited by this paper
• Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206

  2007cited by this paper
• Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

  2007cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• Phase I study of everolimus in pediatric patients with refractory solid tumors.

  2007cited by this paper
• Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018).

  2007cited by this paper
• A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC).

  2006cited by this paper
• Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

  2006cited by this paper
• The mTOR Inhibitor Temsirolimus (CCI-779) Induces Cell Cycle Arrest and Autophagy in Hodgkin Lymphoma (HL) Cell Lines and Enhances the Effect of the PI3-Kinase Inhibitor LY294002.

  2006cited by this paper
• Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival.

  2006cited by this paper
• Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

  2006cited by this paper
• Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies

  2006cited by this paper
• Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

  2005cited by this paper
• Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.

  2005cited by this paper
• mTOR-targeted therapy of cancer with rapamycin derivatives.

  2005cited by this paper
• Constitutive activation of phosphatidyl‐inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR

  2005cited by this paper
• A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas.

  2005cited by this paper
• The tor pathway: a target for cancer therapy

  2004cited by this paper
• Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

  2004cited by this paper
• A pilot study of rituximab in patients with recurrent, classic Hodgkin disease

  2003cited by this paper
• Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

  2002influential reference
• The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.

  2002cited by this paper
• Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

  1999cited by this paper
• Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.

  1997cited by this paper
• Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.

  1993influential reference
• Optimal two-stage designs for phase II clinical trials.

  1989cited by this paper
• Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

  1975cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.

  2026cites this paper
• MEPED as salvage therapy for relapsed/refractory Hodgkin’s lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneck

  2025cites this paper
• Not only a therapeutic target; mTOR in Hodgkin lymphoma and acute lymphoblastic leukemia

  2024cites this paper
• Case report: Sustained complete remission with all-oral MEPED therapy in a patient with Hodgkin’s disease developing resistance to pembrolizumab

  2024cites this paper
• Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the Literature

  2024cites this paper
• Maintenance therapy with Everolimus in patients with refractory or relapsing Hodgkin lymphoma after autologous stem cell transplantation

  2023cites this paper
• The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects

  2023cites this paper
• Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell Resistance

  2023cites this paper
• Role of pembrolizumab in relapsed Hodgkin lymphoma patients

  2023cites this paper
• Drug Repurposing by Tumor Tissue Editing

  2022cites this paper
• EVOLUTION OF DRUG THERAPY FOR CLASSICAL HODGKIN LYMPHOMA

  2022cites this paper
• Targeting metabolism: A potential strategy for hematological cancer therapy

  2022cites this paper
• Identification of prognostic factors in classic Hodgkin lymphoma by integrating whole slide imaging and next generation sequencing.

  2022cites this paper
• Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i)

  2021cites this paper
• The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside

  2021cites this paper
• Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies

  2020cites this paper
• Nanotechnology-Based Targeting of mTOR Signaling in Cancer

  2020cites this paper
• Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

  2020cites this paper
• Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma

  2020cites this paper
• Analysis of Relapsed/Refractory Hodgkin Lymphoma Treated with Autologous Transplantation: A Single-Center Experience

  2020cites this paper
• Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma

  2020cites this paper
• Advanced stage Hodgkin Lymphoma: patient management

  2020cites this paper
• Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

  2020influential citation
• Advances in targeted therapy for malignant lymphoma

  2020cites this paper
• A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin’s lymphoma

  2020cites this paper
• The Management of Older Patients with Hodgkin Lymphoma

  2020cites this paper
• Increased mTOR activation in idiopathic multicentric Castleman disease.

  2020cites this paper
• Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas

  2020cites this paper
• Hodgkin lymphoma

  2020cites this paper
• Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis

  2020cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Hodgkin Lymphoma, Version 2.2020

  2020cites this paper
• 新免疫治疗时代下复发难治性霍奇金淋巴瘤治疗新策略

  2019cites this paper
• Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma

  2019cites this paper
• Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy.

  2019cites this paper
• Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas

  2019cites this paper
• Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy

  2019cites this paper
• A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma

  2018cites this paper
• New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?

  2018cites this paper
• Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma

  2018cites this paper
• Rezidiviertes oder refraktäres klassisches Hodgkin-Lymphom

  2018cites this paper
• Advanced-Stage Hodgkin Lymphoma: New Approaches Based on Novel Therapeutic Agents or Treatment Intensification.

  2018cites this paper
• Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.

  2018cites this paper
• Current and emerging treatment options for a patient with a second relapse of Hodgkin’s lymphoma

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma

  2018cites this paper
• Diagnosis and Treatment of Hodgkin Lymphoma

  2018cites this paper
• NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.

  2018cites this paper
• Transplant strategies in relapsed/refractory Hodgkin lymphoma.

  2018cites this paper
• mTOR Inhibitors, with Special Focus on Temsirolimus and Similar Agents

  2018cites this paper
• Small Molecules in Oncology

  2018cites this paper
• Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma

  2018cites this paper
• Trials Evalua ng Combined Modality Therapy for Early-Stage Hodgkin Lymphoma in the CT Era

  2018cites this paper
• Post-autologous transplant maintenance therapies in lymphoma: current state and future directions

  2018cites this paper
• Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.

  2017cites this paper
• Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience

  2017cites this paper
• A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma

  2017cites this paper
• The Pathobiology and Treatment of Hodgkin Lymphoma. Where do We go from Gianni Bonadonna's Lesson?

  2017cites this paper
• Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab

  2017cites this paper
• Lymphoma Therapy and Adverse Events: Nursing strategies for thinking critically and acting decisively

  2017cites this paper
• Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.

  2017cites this paper
• New agents in relapsed/refractory Hodgkin's lymphoma☆

  2017cites this paper
• Emerging treatment options for the management of Hodgkin’s lymphoma: clinical utility of nivolumab

  2017cites this paper
• Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis

  2017cites this paper
• Immunotherapy for the treatment of Hodgkin lymphoma

  2017cites this paper
• m‐TOR inhibitors and their potential role in haematological malignancies

  2017cites this paper
• Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment?

  2017cites this paper
• Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?

  2017cites this paper
• The evolving role of targeted drugs in the treatment of Hodgkin lymphoma

  2017cites this paper
• Diagnostic applications of nuclear medicine: Lymphomas

  2017cites this paper
• Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma

  2017cites this paper
• Novel treatment concepts in Hodgkin lymphoma

  2017cites this paper
• Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma

  2017cites this paper
• Novel agents in classical Hodgkin lymphoma

  2017cites this paper
• Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies

  2017cites this paper
• Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group

  2016cites this paper
• Pembrolizumab in classical Hodgkin's lymphoma

  2016cites this paper
• Clinical response to everolimus in a patient with Hodgkin's lymphoma harboring a TSC2 mutation

  2016cites this paper
• Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation

  2016cites this paper
• How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant.

  2016cites this paper
• Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective

  2016cites this paper
• Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.

  2016cites this paper
• Targeting Oncoproteins for Molecular Cancer Therapy

  2016cites this paper
• Phase II trial of ofatumumab plus ESHAP (O‐ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first‐line chemotherapy

  2016cites this paper
• Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation

  2016cites this paper
• Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study

  2016cites this paper
• Proliferative Signal Inhibitor in Cardiac Transplantation

  2016cites this paper
• [Treatment of Relapsed and Refractory Hodgkin Lymphoma - Recommendations of the Czech Hodgkin Lymphoma Study Group].

  2016cites this paper
• The Role of PI3K/AKT/mTOR Inhibitors in the Treatment of Hematological Malignancies

  2016cites this paper
• Checkpoint inhibitors in Hodgkin's lymphoma

  2016cites this paper
• DCA as a possible therapy for cutaneous melanome in combination with approved therapeutics

  2016cites this paper
• Biomodulatory metronomic therapy induces PET‐negative remission in chemo‐ and brentuximab‐refractory Hodgkin lymphoma

  2016cites this paper
• A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas.

  2016cites this paper
• Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives

  2016cites this paper
• Emerging Treatment Options for Adolescents and Young Adults with Relapsed or Refractory Lymphoma

  2016cites this paper
• Hodgkin lymphoma: MOPP chemotherapy to PD‐1 blockade and beyond

  2016cites this paper
• Risk-adapted strategies for the treatment of Hodgkin lymphoma

  2015cites this paper
• Primary refractory and early‐relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment

  2015cites this paper
• Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review

  2015cites this paper
• Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products

  2015cites this paper
• Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review

  2015cites this paper